Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

Country/Region

July 06, 2017

Ahead of the G20 summit in Hamburg, where global health is on the agenda for the first time, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) called on G20 leaders to follow through on the declaration made by their health ministers in late May.

July 05, 2017

Two days ahead of the G20 summit in Germany, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) and the Stop TB Partnership released a report that shows countries are lagging behind in tackling tuberculosis (TB), introducing the best diagnostic devices, and implementing globally-recommended policies. The third edition of the “Out of Step” report reviews TB policies and practices in 29[1] countries–which account for 82 percent of the global TB burden–and shows that countries can do much more to prevent, diagnose, and treat people affected by TB.

May 25, 2017

Ahead of the G7 summit that’s starting tomorrow in Italy, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging participating countries to address high medicine prices and drug-resistant infections, which affect people everywhere. Today, across the G7, countries are struggling to pay for new medicines to treat life-threatening illnesses like hepatitis C.

March 24, 2017

NEW YORK, MARCH 24, 2017—Today, World Tuberculosis Day, Doctors Without Borders/Médecins Sans Frontières’ (MSF) is urging pharmaceutical corporations, Sequella and Pfizer, to provide open access to all existing clinical data on a promising drug, sutezolid, to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes. This data, if not released, will take years and resources to replicate, further delaying new treatment options for people living with TB.

January 24, 2017

While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.